HPRA outlines regulatory priorities for 2026–2029

Ireland’s Health Products Regulatory Authority (HPRA) has published its Strategic Plan 2026–2029, setting out four priorities for adapting regulatory oversight to scientific advances, evolving European legislation and challenges affecting the availability...
Your Weekly Life Sciences Digest

Your Weekly Life Sciences Digest

Get an online subscription and you can unlock any article you come across, getting instant emails when our site updates, too.

EU–US GMP mutual recognition becomes fully operational for veterinary medicines

The European Union and the United States have completed the assessment of all EU Member States' competent authorities under the pharmaceutical Good Manufacturing Practice (GMP) Mutual Recognition Agreement (MRA) for veterinary products. As of 29 May 2026, the agreement's veterinary provisions are fully operational, enabling regulators to rely on each other's GMP inspection results and removing the need for routine duplicate inspections of manufacturing sites covered by the agreement. EU-US...

UAE EDE introduces new regulatory controls for peptide products and molecules

Read the official EDE Circular No. 46/2026 and download the full regulatory document in the TOP-Pharma Resource Centre. The Emirates Drug Establishment (EDE) has introduced a comprehensive regulatory framework for peptide products and substances under Circular No. 46/2026, Guideline for Handling Peptide Products and Molecules, issued on 5 November 2026. The 26-page document establishes requirements for regulatory approval, importation, pharmaceutical compounding, quality control, storage, traceability and the use of peptide-containing...

FDA updates its human drug facility inspection framework under ConOps 2.0

The US Food and Drug Administration (FDA) has updated its operating framework for evaluating and inspecting human drug manufacturing facilities. The revised Concept of Operations (ConOps), dated 21 October 2026, formalises the use of remote regulatory assessments and inspection information from international regulatory partners, while clarifying how the agency's drug review and inspection teams coordinate their work. FDA's framework for GMP inspections and facility evaluation The FDA's updated document, Integration of...

FDA clears Evident Vascular’s NVIDIA-powered intravascular ultrasound system with planned AI capabilities

Evident Vascular has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Evident Vascular Guidance System (EVGS), an intravascular ultrasound (IVUS) platform designed for peripheral vascular interventions. The system combines high-resolution ultrasound imaging, proprietary image-processing technology and computing capabilities powered by NVIDIA. The FDA issued its substantial equivalence determination on 28 October 2026 under submission K261648. The device is classified as Class II and was found substantially equivalent...

US courts report 4,082 pending actions in GLP-1 gastrointestinal injury litigation

More than 4,000 actions alleging gastrointestinal injuries associated with GLP-1-based medicines are pending in a US federal multidistrict litigation (MDL). According to the latest statistics published by the US Judicial Panel on Multidistrict Litigation (JPML), 4,082 actions were pending in MDL No. 3094 as of 2 November 2026, while the total number of actions historically recorded in the MDL was 4,196. The litigation involves Novo Nordisk and Eli Lilly, whose...

GMP & Guidance

Documents available for download

EU–US GMP mutual recognition becomes fully operational for veterinary medicines

The European Union and the United States have completed the assessment of all EU Member States' competent authorities under the pharmaceutical Good Manufacturing Practice (GMP) Mutual Recognition Agreement (MRA)...

UAE EDE introduces new regulatory controls for peptide products and molecules

Read the official EDE Circular No. 46/2026 and download the full regulatory document in the TOP-Pharma Resource Centre. The Emirates Drug Establishment (EDE) has introduced a comprehensive regulatory framework for...

FDA updates its human drug facility inspection framework under ConOps 2.0

The US Food and Drug Administration (FDA) has updated its operating framework for evaluating and inspecting human drug manufacturing facilities. The revised Concept of Operations (ConOps), dated 21 October...

FDA proposes framework for individualized gene therapies as CMS expands access

The US Food and Drug Administration (FDA) has proposed a regulatory framework for individualized human genome editing therapies, while the Centers for Medicare & Medicaid Services (CMS) plans to...
spot_img

Professional Interpreters for
GMP Inspections

Clear Communication for Your GMP Inspection.
We provide expert on-site interpreters who understand pharmaceutical terminology to ensure smooth communication with the inspectors.